Nov 16, 2021 Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors Learn More
Nov 8, 2021 Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update Learn More
Oct 25, 2021 Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies Learn More